Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Macrogenics (MGNX) Cost of Revenue (2021 - 2024)

Macrogenics (MGNX) has disclosed Cost of Revenue for 4 consecutive years, with $233000.0 as the latest value for Q4 2024.

  • Quarterly Cost of Revenue rose 42.94% to $233000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $233000.0 through Sep 2025, down 70.01% year-over-year, with the annual reading at $847000.0 for FY2024, 36.83% up from the prior year.
  • Cost of Revenue for Q4 2024 was $233000.0 at Macrogenics, up from $168000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $3.0 million in Q3 2022, with the low at $17000.0 in Q1 2021.
  • Average Cost of Revenue over 4 years is $466750.0, with a median of $172000.0 recorded in 2024.
  • The sharpest move saw Cost of Revenue skyrocketed 718.18% in 2022, then plummeted 97.17% in 2023.
  • Over 4 years, Cost of Revenue stood at $947000.0 in 2021, then tumbled by 87.75% to $116000.0 in 2022, then skyrocketed by 40.52% to $163000.0 in 2023, then soared by 42.94% to $233000.0 in 2024.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $233000.0, $168000.0, and $176000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.